Fundamentals of PET Molecular Imaging in Dementia and Parkinsonism

Overview

PET molecular imaging biomarkers have transformed the diagnosis and understanding of neurodegenerative diseases by enabling in vivo visualization of protein aggregates and neuronal dysfunction. Amyloid and tau PET tracers allow early detection of Alzheimer’s pathology, while FDG-PET reveals characteristic hypometabolism patterns in various dementias and parkinsonian syndromes.

Background

Neurodegenerative diseases are increasingly defined by their molecular pathology rather than clinical symptoms alone, with protein aggregates such as amyloid-β and tau serving as key hallmarks. PET imaging provides sensitive, non-invasive quantification of these molecular targets, facilitating earlier diagnosis and monitoring of disease progression. This biological approach supports the development and evaluation of disease-modifying therapies. The review focuses on PET radiotracers currently used in clinical practice for cognitive impairment and parkinsonism evaluation.

Data Highlights

Key Findings

• Neurodegenerative diseases are increasingly characterized by molecular biomarkers, especially protein aggregates like amyloid-β and tau.
• Amyloid PET tracers detect amyloid plaques years before clinical symptoms of Alzheimer’s disease manifest.
• Fluorine-18 labeled amyloid PET tracers ([18F]florbetapir, [18F]florbetaben, [18F]flutemetamol) offer longer half-life and wider clinical availability compared to [11C]PiB.
• These fluorinated tracers demonstrate high sensitivity (91-98%) and specificity (89-100%) for amyloid plaque detection, validated neuropathologically.
• FDG-PET remains the most widely available tracer, measuring glucose metabolism to detect early brain dysfunction in various dementias and parkinsonian disorders.
• Understanding PET imaging patterns and potential artefacts is essential for accurate interpretation and clinical application.

Clinical Implications

PET molecular imaging enables earlier and more accurate diagnosis of neurodegenerative diseases by visualizing specific proteinopathies and neuronal dysfunction. Clinicians can use amyloid PET to confirm or exclude Alzheimer’s pathology in patients with cognitive impairment, aiding treatment decisions and clinical trial recruitment. Familiarity with tracer characteristics and imaging interpretation enhances diagnostic confidence and patient management.

Conclusion

PET molecular imaging has become indispensable in the biological characterization of neurodegenerative disorders, facilitating early diagnosis and monitoring. The availability of validated amyloid and metabolic PET tracers supports a shift towards biomarker-driven clinical practice in dementia and parkinsonism.

References

1. Jack et al. 2018 -- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
2. Villemagne et al. 2018 -- Tau PET imaging: present and future directions
3. Mosconi et al. 2008 -- FDG-PET in neurodegenerative diseases
4. Klunk et al. 2004 -- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
5. Rowe et al. 2007 -- Imaging amyloid beta in Alzheimer's disease with PET
6. Barthel et al. 2011 -- Amyloid imaging with florbetapir F18
7. Vandenberghe et al. 2010 -- Florbetaben PET imaging for amyloid plaques
8. Thurfjell et al. 2014 -- Clinical use of amyloid PET imaging